Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 10Unknown 4Completed 3Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × olverembatinib × Other hematologic neoplasm × Clear all
NCT03883087 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Ascentage Pharma Group Inc.

Phase 2 Unknown
41 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT03883100 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Ascentage Pharma Group Inc.

Phase 2 Unknown
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

NCT05495035 2023-03-02

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Unknown
22 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05311943 2022-07-29

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Shenzhen Second People's Hospital

Phase 3 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡